A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)
2026年8月28日 更新者:GlaxoSmithKline
A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan in Combination With Immune Checkpoint Inhibition for Maintenance Treatment of Participants With Mismatch Repair Proficient (MMRp) Endometrial Cancer
The purpose of this study is to see how well mocertatug rezetecan (Mo-Rez) in combination with physician's choice of immunotherapy (dostarlimab or pembrolizumab) works as maintenance therapy in participants with advanced or recurrent endometrial cancer (EC) compared with the physician's choice of immunotherapy (dostarlimab or pembrolizumab) alone, which represents the current standard of care.
The study will also assess whether the drug combination is safe and tolerated well by participants compared to standard of care and will help us better understand its impact on Health-Related Quality of Life of participants.
調査の概要
研究の種類
介入
入学 (推定)
610
段階
- フェーズ 3
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前:US GSK Clinical Trials Call Center
- 電話番号:877-379-3718
- メール:GSKClinicalSupportHD@gsk.com
研究連絡先のバックアップ
- 名前:EU GSK Clinical Trials Call Center
- 電話番号:+44 (0) 20 89904466
- メール:GSKClinicalSupportHD@gsk.com
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
いいえ
説明
Inclusion Criteria:
- Is at least 18 years of age and the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the Informed consent form (ICF).
- Has received 6 cycles of first-line therapy (i.e. induction therapy), consisting of platinum-based doublet chemotherapy (e.g., carboplatin/paclitaxel) with immune checkpoint inhibition as part of standard of care (either pembrolizumab or dostarlimab) or via trial Run-In (dostarlimab). Receipt of only 4 cycles of chemotherapy is permitted if chemotherapy was discontinued due to toxicity, provided that the participant received at least 12 weeks of immune checkpoint inhibitor therapy during the induction period.
- Is able to commence C1D1 of study treatment within 3 - 9 weeks of the final dose of first-line therapy.
- Is deemed suitable to continue with maintenance therapy with immune checkpoint inhibition (dostarlimab or pembrolizumab).
- Demonstrates no clinical or radiographic progression of disease per investigator after the final dose of induction therapy. Final dose is defined as the last day that either platinum chemotherapy, taxane chemotherapy or immune checkpoint inhibition was given within the last cycle of induction therapy
- Has histologically confirmed endometrial carcinoma including but not limited to endometrioid, serous, clear cell and endometrial carcinosarcoma. Mixed epithelial carcinomas are permitted.
Meets one of the following criteria:
- Has newly diagnosed stage III disease [2023 International Federation of Gynecology and Obstetrics (FIGO) staging] with measurable residual disease >1 cm after primary debulking surgery (incomplete cytoreduction).
- Has newly diagnosed stage III disease (2023 FIGO staging) that is not suitable for primary debulking surgery with measurable disease.
- Has newly diagnosed stage IV disease (2023 FIGO staging) and any residual disease status (measurable or non-measurable) following debulking surgery. Participants not suitable for primary debulking surgery are also permitted.
- Has recurrent disease and is naïve to systemic anticancer therapy and any disease status (measurable or non-measurable).
- Has recurrent disease after receiving prior neo-adjuvant/adjuvant systemic anticancer therapy and had a recurrence >12 months after last dose of neo-adjuvant/adjuvant treatment. Participants with any disease status (measurable or non-measurable) are permitted.
- Has a tumor demonstrating either Mismatch Repair proficient (MMRp) or Microsatellite stable (MSS).
- Has provided a Formalin fixed, paraffin embedded (FFPE) tumor tissue sample sufficient for the central assessment of B7 homolog 4 protein (B7-H4) expression and MMR (if local MMRp/MSS test result(s) not available), with the result of B7-H4 expression testing available prior to date of randomization.
- Is willing to use adequate contraception. Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Exclusion Criteria:
- Mesenchymal tumors of the uterus (uterine sarcomas) and neuroendocrine uterine cancer.
- Has a malignancy (except disease under study) that has progressed or required active treatment within 36 months prior to date of randomization except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas.
- Any evidence of current Interstitial lung disease (ILD) or pneumonitis or a prior history of ILD or non-infectious pneumonitis.
- Has experienced any of the following with prior immunotherapy: any imAE ≥ Grade 3, immune-mediated severe neurologic events of any grade (e.g., myasthenic syndrome/myasthenia gravis, encephalitis, Guillain-Barré Syndrome, or transverse myelitis), exfoliative dermatitis of any grade (Stevens-Johnson syndrome [SJS], Toxic Epidermal Necrolysis [TEN], or Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS] syndrome, or myocarditis of any grade.
- Has ongoing adverse reaction(s) from prior therapy that has(have) not recovered to ≤ Grade 1 or to the baseline status preceding prior therapy, excluding alopecia, hearing loss, vitiligo, endocrinopathy managed with replacement therapy, and Grade 2 neuropathy, or adverse reactions that the investigator, with the agreement of the sponsor, considers to be not clinically relevant for the tolerability of study intervention in the current clinical study.
- Has had any major surgery within 28 days prior to date of C1D1 or received focal radiotherapy within 21 days prior to date of C1D1.
- Has received treatment with an investigational agent within 30 days prior to C1D1.
- Has received prior therapy with topoisomerase I inhibitors (e.g. irinotecan or topotecan) or Antibody-Drug Conjugate (ADC)with a topoisomerase I inhibitor warhead, B7-H4 targeted therapy, or immune checkpoint inhibitor.
- Has received treatment with inhibitors of P-glycoprotein (P-gp) or Breast cancer resistant protein (BCRP), or OATP1B1/1B3 transporterswithin 7 days prior to the date of C1D1. Inducers of P-gp should be discontinued for at least 14 days prior to the date of C1D1.
- Has received any transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including Granulocyte-Colony Stimulating Factor [G-CSF], Granulocyte-Macrophage Colony-Stimulating Factor [GM-CSF], or recombinant erythropoietin) within 14 days prior to C1D1.
- Has an Alanine aminotransferase (ALT) value >2.5 × Upper limit of normal (ULN) or for participants with documented liver metastases/tumor infiltration has an ALT value >5 × ULN.
- Has a total bilirubin value >1.5 × ULN.
- Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice. Participants who exhibit these signs or symptoms as a result of the malignancy under investigation and whose conditions are deemed adequately controlled by the investigator may be eligible for inclusion.
- Has Corrected QT interval (QTc) >470 milliseconds (msec).
- Has a history of symptomatic pericarditis of any cause within 6 months prior to screening or evidence of cardiac abnormalities within 12 months prior to screening such as serious, uncontrolled cardiac arrhythmia or clinically significant ECG abnormalities.
- Has any active renal condition (e.g., infection, requirement for dialysis, or any other significant renal condition that could affect the participant's safety).
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Mocertatug rezetecan plus physician's choice of immunotherapy (dostarlimab or pembrolizumab)
Participants will receive Mocertatug rezetecan along with physician's choice of immunotherapy (Dostarlimab or Pembrolizumab)
|
ペムブロリズマブが投与されます
ドスタリマブが投与されます
Mocertatug rezetecan will be administered
|
|
アクティブコンパレータ:Physician's choice of immunotherapy (dostarlimab or pembrolizumab)
Participants will receive physician's choice of immunotherapy (Dostarlimab or Pembrolizumab alone)
|
ペムブロリズマブが投与されます
ドスタリマブが投与されます
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression free survival (PFS) by BICR assessment
時間枠:Up to approximately 143 weeks
|
PFS is defined as the time from the date of randomization to the date of first documented Progressive Disease (PD) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) by Blinded independent central review (BICR) assessment or death from any cause, whichever occurs first
|
Up to approximately 143 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Survival (OS)
時間枠:Up to approximately 260 weeks
|
OS is defined as the time from the date of randomization to the date of death due to any cause
|
Up to approximately 260 weeks
|
|
PFS by investigator assessment
時間枠:Up to approximately 143 weeks
|
PFS is defined as the time from the date of randomization to the date of first documented PD per RECIST 1.1 by investigator assessment or death from any cause, whichever occurs first
|
Up to approximately 143 weeks
|
|
Objective response rate (ORR) by investigator assessment
時間枠:Up to approximately 260 weeks
|
ORR is defined as the percentage of participants with best overall response of either complete response (CR) or partial response (PR) per RECIST 1.1 by investigator assessment
|
Up to approximately 260 weeks
|
|
ORR by BICR assessment
時間枠:Up to approximately 260 weeks
|
ORR is defined as the percentage of participants with best overall response of either CR or PR per RECIST 1.1 by BICR assessment
|
Up to approximately 260 weeks
|
|
Duration of Response (DOR) by investigator assessment
時間枠:Up to approximately 260 weeks
|
DOR is defined as the time from the date of first documented objective response (CR or PR) to the date of first documented PD per RECIST 1.1 by investigator assessment or death from any cause, whichever comes first
|
Up to approximately 260 weeks
|
|
DOR by BICR assessment
時間枠:Up to approximately 260 weeks
|
DOR is defined as the time from the date of first documented objective response (CR or PR) to the date of first documented PD per RECIST 1.1 by BICR assessment or death from any cause, whichever comes first
|
Up to approximately 260 weeks
|
|
Progression Free Survival on subsequent line of therapy (PFS2)
時間枠:Up to approximately 260 weeks
|
PFS2 is defined as the time from the date of randomization to the date of first documented investigator-assessed clinical or radiographical progression following the first subsequent anticancer therapy and after the progression event used for PFS, or death from any cause, whichever occurs first
|
Up to approximately 260 weeks
|
|
Time to first subsequent therapy or death (TFST)
時間枠:Up to approximately 260 weeks
|
TFST is defined as the time from the date of randomization to the date of initiation of subsequent therapy or death from any cause, whichever occurs first
|
Up to approximately 260 weeks
|
|
Time to second subsequent therapy (TSST)
時間枠:Up to approximately 260 weeks
|
TSST is defined as the time from the date of randomization to the date of initiation of second subsequent therapy or death from any cause, whichever occurs first
|
Up to approximately 260 weeks
|
|
Serum pharmacokinetic (PK) concentration of Mo-Rez (conjugated antibody and payload)
時間枠:Up to approximately 260 weeks
|
Up to approximately 260 weeks
|
|
|
Number of participants with Antidrug antibody (ADA) or Neutralizing Antibody (NAb) against Mo-Rez
時間枠:Up to approximately 260 weeks
|
Up to approximately 260 weeks
|
|
|
Titers of ADA against Mo-Rez
時間枠:Up to approximately 260 weeks
|
Up to approximately 260 weeks
|
|
|
Number of participants with Treatment-emergent adverse event (TEAEs), Adverse event of special interest (AESIs), Immune-mediated adverse event (imAEs) and Treatment-emergent serious adverse event (TESAEs)
時間枠:Up to approximately 260 weeks
|
Up to approximately 260 weeks
|
|
|
Number of participants with TEAEs leading to dose modifications or study intervention discontinuation
時間枠:Up to approximately 260 weeks
|
Up to approximately 260 weeks
|
|
|
Number of participants with changes in vital signs, laboratory tests (hematology and clinical chemistry), and Electrocardiogram (ECG)
時間枠:Up to approximately 260 weeks
|
Up to approximately 260 weeks
|
|
|
Change from baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) score
時間枠:Up to approximately 260 weeks
|
The EORTC QLQ-C30 includes 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies.
Participants responses on these items are averaged and then transformed to scores ranging from 0 to 100.
For items related to function and global health status, a higher score indicates better functioning or a better overall state of health, while, for symptom-related items, a higher score denotes more severe symptoms.
|
Up to approximately 260 weeks
|
|
Change from baseline in EORTC QLQ- Endometrial Cancer Module (EN24) score
時間枠:Up to approximately 260 weeks
|
The EORTC QLQ-EN24 includes a 24-item questionnaire for evaluating endometrial cancer-specific symptoms and concerns in participants of cancer clinical studies.
Participants responses are averaged and then transformed to a score ranging from 0 to 100.
For functional and global health items, a higher score indicates better functioning or a better overall state of health, while for symptom items, a higher score indicates more severe symptoms.
|
Up to approximately 260 weeks
|
|
Time to deterioration (TTD) of EORTC QLQ-EN24
時間枠:Up to approximately 260 weeks
|
TTD is defined as the time from date of randomization to the first confirmed clinically meaningful deterioration on any of the domains of EORTC QLQ-EN24: lymphoedema, urological symptoms, gastrointestinal symptoms, and pain in back and pelvis
|
Up to approximately 260 weeks
|
|
TTD of EORTC QLQ-C30
時間枠:Up to approximately 260 weeks
|
TTD is defined as the time from date of randomization to the first confirmed clinically meaningful deterioration on any of the domains of EORTC QLQ-C30: physical functioning, role functioning, and Global Health Status (GHS) /Quality of Life (QoL)
|
Up to approximately 260 weeks
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
スポンサー
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (推定)
2026年9月3日
一次修了 (推定)
2029年7月23日
研究の完了 (推定)
2031年9月18日
試験登録日
最初に提出
2026年6月29日
QC基準を満たした最初の提出物
2026年6月29日
最初の投稿 (実際)
2026年7月6日
学習記録の更新
投稿された最後の更新 (実際)
2026年9月1日
QC基準を満たした最後の更新が送信されました
2026年8月28日
最終確認日
2026年8月1日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 224039
- 2025 (米国 NIH グラント/契約:Faculty of Social Sciences Scientific Grant at the University of Gdańsk)
- 2025-523363-37-00 (Ctis)
- ENGOT-en33 (その他の識別子:European Network of Gynaecological Oncological Trial Groups (ENGOT))
- GOG-3130 (その他の識別子:Gynaecologic Oncology Group (GOG))
- APGOT-EN5 (その他の識別子:Asia-Pacific Gynaecologic Oncology Trials Group (APGOT))
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
はい
IPD プランの説明
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents.
Data sharing is subject to certain criteria, conditions, and exceptions.
For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
IPD 共有時間枠
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
IPD 共有アクセス基準
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place.
Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
はい
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。